Drug Research
Pistoia Alliance President Warns Pharmaceutical Industry Not to Undo the Advances it has Made During the Pandemic
Tackling global public health crises will require industry to continue overcoming trust issues and accelerate the safe sharing of anonymized patient data
Dr Steve Arlington, President of The Pistoia Alliance, a global not-for-profit advocating for greater collaboration in biopharma, is...
Drug Research
Syntegon and Vetter win PDA Drug Delivery Innovation Award for Versynta microBatch
Together with Vetter, an international pharmaceutical service provider for injectables, Syntegon (formerly Bosch Packaging Technology) has won the PDA Drug Delivery Innovation Award. In the "Partnership Innovation" category, the Parental Drug Association (PDA) honors development projects by pharmaceutical and...
Drug Research
Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced that the European Medicines Agency (EMA) has authorized a third dose of the Moderna COVID-19 vaccine (Spikevax) given at least 28 days after the second dose...
Drug Research
TriLink BioTechnologies Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea
TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, announced that it expects to supply its proprietary CleanCap® mRNA capping technology and the modified nucleoside, uridine triphosphate,...
Drug Research
Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US clinical trials
Clarity Pharmaceuticals, an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and Evergreen Theragnostics, Inc., a radiopharmaceutical contract manufacturer, are pleased to announce that the companies have entered into a Targeted Copper...
Drug Research
Merck Licenses Foundational CRISPR Technology to Cellecta, Paving Path for Development of Next-Generation Treatments
Merck, a leading science and technology company, announced that its Life Science business sector has signed an agreement licensing its patented CRISPR-Cas9 technology to Cellecta, Inc., a functional genomics products and services provider based in Mountain View, California, USA....
Drug Research
Phesi Big Data Analysis of Over 200,000 Hepatitis B and C Patients Identifies Typical Patient to Help Drive Forward Disease Elimination Goals
Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, has analyzed data from 209,860 hepatitis B (HBV) and C (HCV) patients, from 940 trial arms/cohorts to build a picture of the “typical” patient and identify...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read